Disclosed is a novel combination therapy using Ecyd, which has a remarkable anti-tumor effect and has few adverse side effects. Specifically disclosed is an anti-tumor agent comprising a combination of 1-(3-C-ethynyl-β-D-ribopentofuranosyl)- cytosine or a salt thereof and carboplatin.